Lack of association between serum paraoxonase 1 activities and increased oxidized low-density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes mellitus

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 4, 2003, Pages 1711-1716

  Kopprasch, Steffi ^a   Pietzsch, Jens ^b   Kuhlisch, Eberhard ^a   Graessler, Juergen ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROPHENYLACETIC ACID; ACETIC ACID DERIVATIVE; ARGININE; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; GLUTAMINE; OXIDIZED LOW DENSITY LIPOPROTEIN; PARAOXON; PHENYLACETIC ACID; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC MICROANGIOPATHY; DISEASE COURSE; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; ENZYME LOCALIZATION; ENZYME SUBSTRATE; FEMALE; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; PHENOTYPE; PRIORITY JOURNAL; REGULATORY MECHANISM;

ADULT; AGED; ARYLDIALKYLPHOSPHATASE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; ESTERASES; FEMALE; GLUCOSE INTOLERANCE; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; INSULIN; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PARAOXON; PHENOTYPE; PHENYLACETATES; SUBSTRATE SPECIFICITY;

EID: 0038697963     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-021561     Document Type: Article

References (36)

1. Mackness MI, Arrol S, Durrington PN 1991 Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286:152-154
2. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M 1995 Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96:2882-2891
3. Steinberg D 1997 Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 272:20963-20966
4. Hanefeld M, Koehler C, Henkel E, Fuecker K, Schaper F, Temelkova-Kurktschiev T 2000 Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD study. Diabetic Med 17:835-840
5. Kopprasch S, Pietzsch J, Kuhlisch E, Fuecker K, Temelkova-Kurktschiev T, Hanefeld M, Kühne H, Julius U, Graessler J 2002 In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance. Diabetes 51:3102-3106
6. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN 1995 Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 15:1812-1818
7. Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuasha B, Miller JE, Boulton AJM, Durrington PN 1998 Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139:341-349
8. Ikeda Y, Suehiro T, Inoue M, Nakauchi Y, Morita T, Arii K, Ito H, Kumon Y, Hashimoto K 1998 Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism 47:598-602
9. 1999 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 22(Suppl 1):S5-S19
10. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Bennett PH, Howard BV 1997 Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544
11. de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ 2001 Relation of impaired fasting and post-load glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA 285:2109-2113
12. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiumkaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, Finnish Prevention Study Group 2001 Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1334-1350
13. Pietzsch J, Subat S, Nitzsche S, Leonhardt W, Schentke KU, Hanefeld M 1995 Very fast ultracentrifugation of serum lipoproteins influence on lipoprotein separation and composition. Biochim Biophys Acta 1254:77-88
14. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D 1998 Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98:1487-1494
15. Dantoine TF, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G, Leroux-Robert C 1998 Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 9:2082-2088
16. Eckerson HW, Wyte CM, La Du BN 1983 The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 35:1126-1138
17. 55 genotype. Arterioscler Thromb Vasc Biol 20:2441-2447
18. Sakai T, Matsuura B, Onji M 1998 Serum paraoxonase activity and genotype distribution in Japanese patients with diabetes mellitus. Intern Med 37:581-584
19. Mackness B, Durrington PN, Abuashia B, Boulton AJ, Mackness MI 2000 Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci 98:355-363
20. Baynes JW, Thorpe SR 2000 Glycoxidation and lipoxidation in atherogenesis. Free Rad Biol Med 28:1708-1716
21. Hedrick CC, Thorpe SR, Fu MX, Harper CM, Yoo J, Kim SM, Wong H, Peters AL 2000 Glycation impairs high-density lipoprotein function. Diabetologia 43:312-320
22. Ferretti G, Bacchetti T, Marchionni C, Caldarelli L, Curatola G 2001 Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol 38:163-169
23. Deakin S, Leviev I, Gomaraschi M, Calabresi L, Franceschini G, James RW 2002 Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J Biol Chem 277:4301-4308
24. Pietzsch J, Julius U, Nitzsche S, Hanefeld M 1998 In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes 47:1928-1934
25. Rashid S, Uffelman KD, Lewis GF 2002 The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. J Diabetes Compl 16:24-28
26. Yamada A, Shoji T, Tahara H, Emoto M, Nishizawa Y 2001 Effect of insulin resistance on serum paraoxonase activity in a nondiabetic population. Metabolism 50:805-811
27. Kopprasch S, Pietzsch J, Kuhlisch E, Graessler J, Chemiluminescence as a tool to assess hyperglycemia-induced systemic oxidative stress in different insulin-resistant states. Abstracts of the 12th International Symposium on Bioluminescence and Chemiluminescence, Cambridge, 2002. Luminescence 17:94 (Abstract)
28. Durrington PN, Mackness B, Mackness MI 2001 Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21:473-480
29. Aubo C, Senti M, Marrugat J, Tomas M, Vila J, Sala J, Masia R 2000 Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in the human paraoxonase gene and diabetes mellitus. Eur Heart J 21:33-38
30. Pfohl M, Koch M, Enderle MD, Kuhn R, Fullhase J, Karsch KR, Haring HU 1999 Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes 48:623-627
31. Ruiz J, Blanche H, James RW, Garin MCB, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P 1995 Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 346:869-872
32. Osei-Hyiaman D, Hou L, Mengbai F, Zhiyin R, Zhiming Z, Kano K 2001 Coronary artery disease risk in Chinese type 2 diabetics: is there a role for paraoxonase 1 gene (Q192R) polymorphism? Eur J Endocrinol 144:639-644
33. Cao H, Girard-Globa A, Serusclat A, Bernard S, Bondon P, Picard S, Berthezene F, Moulin P 1998 Lack of association between carotid intima-media thickness and paraoxonase gene polymorphism in non-insulin dependent diabetes mellitus. Atherosclerosis 138:361-366
34. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN 1998 Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 423:57-60
35. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Erogul J, Hsu C, Dunlop C, La Du B 1998 Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities. Arterioscler Thromb Vasc Biol 18:1617-1624
36. Stocker R 1994 Lipoprotein oxidation: mechanistic aspects, methodological approaches and clinical relevance. Curr Opin Lipidol 5:422-433